Compare SOPH & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOPH | JGH |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 292.3M |
| IPO Year | 2021 | N/A |
| Metric | SOPH | JGH |
|---|---|---|
| Price | $4.51 | $12.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 76.0K | 73.9K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $73,297,000.00 | N/A |
| Revenue This Year | $18.32 | N/A |
| Revenue Next Year | $15.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.66 | N/A |
| 52 Week Low | $2.58 | $10.36 |
| 52 Week High | $5.30 | $12.85 |
| Indicator | SOPH | JGH |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 49.03 |
| Support Level | $4.60 | $12.39 |
| Resistance Level | $4.84 | $12.50 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 17.51 | 59.98 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.